Non-small cell lung cancer (NSCLC) and hepatocellular liver carcinoma are tumors that respond poorly to anticancer drugs. Aclarubicin (ACL) is a second generation trisaccharide anthracycline drug used for the treatment of a variety of solid tumors and hematological malignancies. ACL toxicity and mechanism of action still remains problematic and not well understand. The aim of this research is to examine the ability of ACL to induce apoptosis and necrosis in the human non-small cancer cell line A549 and human hepatocellular liver carcinoma cell line HepG2. Trypan blue dye exclusion and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were used to estimate cytotoxicity of the drug. Caspase-3 and TUNEL (TdT-mediated dUTP Nick-End Labeling) assays were used to evaluate apoptosis. The results suggest that aclarubicin is a more effective than doxorubicin in inducing apoptosis as well as necrosis and in both A549 and HepG2 cells.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/10799 must be provided.

1. The combined effect of daunorubicin and glutaraldehyde on the red blood cells (RBCs) membrane proteins